$INCY

Tray Thomas sold $200K of INCY

Tray Thomas (Principal Accounting Officer) sold 2,051 shares of INCYTE CORP (INCY) at $97.35 ($0.20M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tray Thomas
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
medium confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings under a 10b5-1 plan; it does not include guidance, litigation, or operational updates.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but the 10b5-1 structure makes it unlikely to drive a durable repricing by itself.

03

What to watch

Insider sales can be offset by other insider buys or option exercises not shown here; also, the filing does not reveal intent beyond the pre-arranged plan.

Relevance 3/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-26

Background

This is an SEC Form 4 insider transaction disclosure for Incyte, reported by Tray Thomas (Principal Accounting Officer).

Company-level read

Ticker impact

$INCYNeutralMedium confidence
Context

Incyte Form 4 shows Tray Thomas sold 2,051 shares at $97.35 on a 10b5-1 plan, disclosing $199,664.85 in insider sales.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other new fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 and is time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven under the 10b5-1 schedule and should not be treated as bearish signal.

Key entities

  • Incyte Corp

    Subject of the Form 4 insider transaction disclosure.

  • Tray Thomas

    Principal Accounting Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MIRMHighAI 9/10

Mirum wins FDA Atebrioz approval for FOP patients 12+

Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.

$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

$INCYHighAI 8/10

EMA OKs Two Options for Refractory Inflammatory Conditions

The EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.